No Data
No Data
What's Left in Cassava After Phase 3 Setback for Alzheimer's Drug
Express News | Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Cassava Sciences Cut to Neutral From Buy by HC Wainwright & Co.
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Vincebcb : I as long here and unfortunately the drug did not meet the ending point… there is no other in the pipe… do not waste money here…